Ilyas Shaikh, MD
Neurology · Mobile, ALNPI 1023099645
Payments from drug & device makers
Across 306 payments — averaging $20.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- SK Life Science, Inc.$1K
- Eisai Inc.$604
- UCB, Inc.$467
- Sunovion Pharmaceuticals Inc.$440
- Lilly USA, LLC$347
- plus $2K from 27 others
What the payments were for
- Food & beverage$6,246100%
- Education$10%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 85 | $1,267 |
| SK Life Science, Inc. | 44 | $1,232 |
| Eisai Inc. | 26 | $604 |
| UCB, Inc. | 13 | $467 |
| Sunovion Pharmaceuticals Inc. | 26 | $440 |
| Lilly USA, LLC | 19 | $347 |
| Teva Pharmaceuticals USA, Inc. | 13 | $238 |
| Supernus Pharmaceuticals, Inc. | 16 | $234 |
| EMD Serono, Inc. | 8 | $183 |
| Sanofi | 7 | $181 |
| Sumitomo Pharma America, Inc. | 5 | $105 |
| Bristol Myers Squibb | 5 | $87 |
| Genentech USA, Inc. | 2 | $87 |
| Johnson & Johnson | 4 | $86 |
| Amgen | 4 | $73 |
| Biogen | 4 | $68 |
| Boston Scientific | 1 | $58 |
| Biohaven Pharmaceuticals, Inc. | 3 | $57 |
| Axsome Therapeutics, Inc. | 2 | $49 |
| Neurocrine Biosciences, Inc. | 3 | $48 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $44 |
| Neurelis, Inc. | 2 | $42 |
| Novartis | 2 | $41 |
| Lundbeck LLC | 1 | $34 |
| Abbott | 1 | $30 |
| Vanda Pharmaceuticals Inc. | 1 | $25 |
| Amneal Pharmaceuticals LLC | 1 | $22 |
| Neuronetics, Inc. | 1 | $21 |
| GE HealthCare | 1 | $17 |
| Assertio Therapeutics, Inc. | 1 | $17 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $17 |
| Mallinckrodt Hospital Products Inc. | 1 | $17 |
| Pfizer | 1 | $13 |
How this compares
$6,247 in reported general payments places this provider in the 55th percentile of 255 neurology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AptiomEslicarbazepine Acetate | 40 | $62,263 |
| UbrelvyUbrogepant | 53 | $60,317 |
| XcopriCenobamate | 22 | $41,199 |
| FycompaPerampanel | 21 | $27,631 |
| QuliptaAtogepant | 11 | $17,141 |
| Nurtec OdtRimegepant Sulfate | 13 | $14,938 |
| XareltoRivaroxaban | 13 | $7,256 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 484 | $6,076 |
| Diclofenac Sodium | 72 | $3,533 |
| Divalproex Sodium ErDivalproex Sodium | 26 | $3,480 |
| Tizanidine Hcl | 245 | $1,709 |
| Lamotrigine | 56 | $1,582 |
| Dexlansoprazole DrDexlansoprazole | 11 | $1,550 |
| Lamotrigine ErLamotrigine | 12 | $1,538 |
| Celecoxib | 89 | $1,340 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieUbrelvy, Qulipta | $1,267 | $77,45764 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $440 | $62,26340 claims |
| SK Life Science, Inc.Xcopri | $1,232 | $41,19922 claims |
| Eisai Inc.Fycompa | $604 | $27,63121 claims |
| PfizerNurtec Odt | $13 | $14,93813 claims |
| Johnson & JohnsonXarelto | $86 | $7,25613 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 255 neurology providers in Alabama.
Other neurology in Mobile
- Daniel DeesMobile$894K
- Hayden LongMobile$386K
- William KilgoMobile$334K
- John HintonMobile$270K
- Charles MarkleMobile$212K
- Bassam BassamMobile$197K
- Dean NaritokuMobile$164K
- Matthew McLeanMobile$113K
- Laura MintoMobile$92K
- Steve CordinaMobile$75K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.